Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2005

View Archived Issues

Cenix and Instituto de Medicina Molecular work together in malaria

Pivotal phase III study begins for Technosphere Insulin

Enrollment nears completion in ARISE study of AGI-1067

Sumitomo licenses amrubicin hydrochloride to Conforma Therapeutics

First phase III study begins for Evizon in wet AMD

Peplin progresses PEP-005 Topical for actinic keratosis

Altana and Pfizer terminate Daxas collaboration

Paradigm signs agreement with Ortho-McNeil in pain and urinary incontinence

Agensys submits IND for phase I study of AGS-PSCA

Johnson & Johnson completes acquisition of Peninsula Pharmaceuticals

New approval for Topamax

Genzyme acquisition of Bone Care International approved by shareholders

Novel analgesics reported in patent literature

Procyon reflects on FY2004

Recent patents cover novel antiinfective agents

Valera seeks Danish approval for Vantas

SR Pharma to acquire Atugen

Factor Xa inhibitors, PAI-1 inhibitors in early development

ZK-187638 is neuroprotective after permanent focal cerebral ischemia in mice

SUN-N5147 mediates potent antiischemic effects in rats

Sant-7 potentiates the effect of dexamethasone against multiple myeloma

Fujisawa scientists discover selective and orally active IP receptor agonist

Kos inhaled insulin shows promise as adjunct therapy for type 2 diabetes

Preclinical evidence confirms the antidiabetic effects of CKD-501

SSR-180575 demonstrates antiischemic effects in cardiac ischemia model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...